Dx-focused R&D promises policy revolution in pneumonia care
This article was originally published in Clinica
Researchers at the US' John Hopkins Bloomberg School of Public Health are promising to radically update the diagnostic foundation of pneumonia care. The Baltimore, Maryland centre has been awarded grants totalling $43m to update the aetiology of the disease and its management. The central project, termed PERCH (Pneumonia Etiology Research for Child Health), will focus on paediatric pneumonia in the developing world, "using state-of-the-art diagnostics".
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.